Article Text

Download PDFPDF

2022-RA-758-ESGO Pretreatment 18F-FDG PET/CT metabolic parameters as predictors of non-complete cytoreduction in patients with epithelial ovarian cancer
  1. Lidia Sancho Rodriguez1,
  2. Luis Chiva de Agustín2,
  3. Félix Boria Alegre2,
  4. Luisa Sanchez Lorenzo2,
  5. Teresa Castellanos Alarcón2,
  6. Daniel Vazquez Vicente2,
  7. Vicky Betech Antar3,
  8. Antonio Gonzalez Martin2,
  9. Laura García Belaustegui2,
  10. Teresa Iscar Galan2,
  11. Angela Bronte Viedma3,
  12. Enrique Maria Chacon Cruz3,
  13. Jose Angel Minguez Milio3,
  14. Andres Alcazar Peral2,
  15. Guillermo Gallardo Madueño2,
  16. Nabil Manzour Sifontes3,
  17. Carmen Beorlegui Arteta4,
  18. Felix Mauricio Cambeiro Vazquez2,
  19. Jaime Espinos Jimenez2,
  20. Monica Gutierrez Martinez2,
  21. Jacobo Palma Delgado2,
  22. Juan Luis Alcazar Zambrano3 and
  23. MJ Garcia-Velloso3
  1. 1Nuclear Medicine, Clínica Universidad de Navarra, Madrid, Spain
  2. 2Clínica Universidad de Navarra, Madrid, Spain
  3. 3Clínica Universidad de Navarra, Pamplona, Spain
  4. 4Universidad de Navarra, Pamplona, Spain


Introduction/Background The objective of this study was to analyse the utility of pretreatment 18F-FDG-PET/CT metabolic parameters to predict non-complete cytoreduction in patients with epithelial ovarian cancer.

Abstract 2022-RA-758-ESGO Table 1

Sample characteristics and relation to non-complete cytoreduction

Methodology Transversal study on 50 patients with epithelial ovarian cancer at Clínica Universidad de Navarra who underwent pretreatment 18F-FDG-PET/CT and subsequent debulking surgery (R0 = complete, R1 = non-complete). The supra- and infradiaphragmatic metabolic active disease (primary tumor, peritoneal carcinomatosis and lymph nodes) visualized in the 18F-FDG-PET/CT was segmented using Syngo.via (automatic thresholding at 40% SUVmax and manual corrections). The extent and distribution of the peritoneal carcinomatosis was evaluated globally and throughout abdominopelvic regions. The presence of pathological 18F-FDG uptake of the ascites was also evaluated. Metabolic parameters studied were metabolic active tumor volume (MTV) and total lesion glycolysis (TLG, defined as MTVxSUVmean), calculated for each segmented region and for the whole disease. Other variables studied were age, FIGO and histological tumor type. The dependent variable was non-complete cytoreduction. Data were described by median (IQR) and frequency (%). Chi-squared and median test were used to compare groups and ROC analysis to dichotomize continuous variables. Predictors of non-complete cytoreduction were analysed by multiple logistic regression.

Results Patient´s characteristics are listed in table 1. Eleven patients (22%) showed non-complete cytoreduction, mostly associated to pathological uptake in ascites (60 vs 12,5%; OR= 10.5 95%CI: 2.2–50.7; p= 0.004), total MTV >192 (45.0 vs 6.7%; OR=11.5; 95%CI: 2.1–61.7; p=0.007; AUC=0.818) and MTV value of the whole infradiaphragmatic disease >209 (56.3 vs 5.9%; OR= 20.6; 95%CI: 3.6–116.8; p=0.010; AUC=0.818). Only the MTV of the whole infradiaphragmatic disease retains signification in the adjusted model.

Conclusion Despite the small sample size, this initial study highlights the possible role of some 18F-FDG-PET/CT metabolic parameters as predictors of non-complete cytoreduction in patients with epithelial ovarian cancer. Further validation in larger series is needed.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.